CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...

Discover the latest advancements in HIV prevention and how they offer hope for reducing infections, especially in the Black ...

Among treatment-naive people with HIV, dolutegravir/lamivudine showed viral suppression comparable with those of other ...

The government provides HIV medicines free of charge. Yet in one Indigenous territory, cases and deaths are increasing at an ...

A new campaign to address misconceptions and reduce stigma around HIV in Ireland has been launched by the HSE.

Hopkins said that lenacapavir was expected to be reviewed by the U.S. Food and Drug Administration in 2025, with the potential to dramatically reduce HIV infection. "This will be a critical next step ...

The Supreme Court said Friday it will review the constitutionality of the Affordable Care Act’s no-cost coverage mandates for ...

For years, John Fleischman carried the journal of his late mentor, who died from HIV/AIDS. He finally found the perfect home ...

The HSE has launched a campaign to explain advances in HIV treatment and to highlight how delaying going to the doctor is ...

Every week, 4000 young women contract HIV. Discover hidden barriers to prevention and innovative solutions that can change ...

Drought and heavy rainfall also increased the risk of HIV and sexually transmitted infections (STIs), particularly among ...

Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and ...